ArticleCureus2025
Carcinoembryonic Antigen (CEA) Elevation in Routine Screening Unveils Stage IV Lung Adenocarcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carcinoembryonic antigen (CEA) is a tumor marker most often associated with colorectal cancer, but elevated levels may also indicate other malignancies, including lung cancer. Although not recommended as a standalone screening or diagnostic tool, persistent elevation in CEA levels may warrant further investigation. This case report describes a 71-year-old woman who was found to have progressively rising CEA levels during routine private health screening despite being asymptomatic. Initial workup, including colonoscopy, revealed no evidence of colorectal malignancy. However, further evaluation prompted by new respiratory symptoms and imaging findings led to the diagnosis of Stage IVa lung adenocarcinoma. This case underscores the importance of a comprehensive diagnostic approach in patients with unexplained tumor marker elevation. It highlights the potential role of primary care in identifying atypical presentations of serious conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.